1
|
Hazo JB, Brunn M, Wykes T, McDaid D, Dorsey M, Demotes-Mainard J, van der Feltz-Cornelis CM, Wahlbeck K, Knappe S, Meyer-Lindenberg A, Obradors-Tarragó C, Haro JM, Leboyer M, Chevreul K. European mental health research resources: Picture and recommendations of the ROAMER project. Eur Neuropsychopharmacol 2019; 29:179-194. [PMID: 30579654 DOI: 10.1016/j.euroneuro.2018.11.1111] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2018] [Revised: 11/13/2018] [Accepted: 11/15/2018] [Indexed: 11/29/2022]
Abstract
As part of the Roamer project, we sought to have a picture of the available mental health research (MHR) funding, capacity-building and infrastructures resources and to establish consensus-based recommendations that would allow an increase of European MHR resources and enable better use and accessibility to them. The methods fell into three sections (i) a review of the literature, (ii) a mental health-related keywords search within the Cordis®, On-Course® and Meril® databases which contain information on European research funding, training and infrastructures. These reviews provided an overview that was presented to (iii) two experts workshops with 28 participants drawn from academic which identified gaps and produced recommendations. The literature review illustrates the debates in the scientific community on funding, training and infrastructures. The database searches estimated the fraction of health research resources available for mental health. Eight overarching goals for MHR resources were identified by the workshops; each of them was carried out with several practical recommendations. Resources for MHR are scarce considering the burden of mental disorders, the high rate of return of MHR and the under-investment of the field. The recommendations are urgently warranted to increase resources and their optimal access and use.
Collapse
Affiliation(s)
- Jean-Baptiste Hazo
- ECEVE, UMRS 1123, Université Paris Diderot, Sorbonne Paris Cité, INSERM, Paris, France; AP-HP, URC-Eco, DHU PePSY, F-75 004 Paris, France; Fondation FondaMental, French Scientific Foundation, Créteil, France; World Health Organization Collaborating Centre for Research and Training in Mental Health, CCOMS, Lille 59260, Hellemmes, France.
| | - Matthias Brunn
- ECEVE, UMRS 1123, Université Paris Diderot, Sorbonne Paris Cité, INSERM, Paris, France; AP-HP, URC-Eco, DHU PePSY, F-75 004 Paris, France; Fondation FondaMental, French Scientific Foundation, Créteil, France
| | - Til Wykes
- Institute of Psychiatry, Psychology and Neuroscience, King's College London, South London and Maudsley NHS Foundation Trust, UK
| | - David McDaid
- PSSRU, London School of Economics and Political Science, London, UK
| | - Maya Dorsey
- ECEVE, UMRS 1123, Université Paris Diderot, Sorbonne Paris Cité, INSERM, Paris, France; AP-HP, URC-Eco, DHU PePSY, F-75 004 Paris, France; Fondation FondaMental, French Scientific Foundation, Créteil, France
| | | | - Christina M van der Feltz-Cornelis
- Department of Health Sciences, MHARG, University of York, York, United Kingdom; Tranzo Department, Tilburg University, Tilburg, The Netherlands
| | | | - Susanne Knappe
- Institut für Klinische Psychologie und Psychotherapie, Behaviorale Epidemiologie & Center for Clinical Epidemiology and Longitudinal Studies, Technische Universität Dresden, Chemnitzer Str. 46, 01187 Dresden, Germany
| | - Andreas Meyer-Lindenberg
- Medical Faculty Mannheim, Central Institute of Mental Health, University of Heidelberg, 68159 Mannheim, Germany
| | | | - Josep Maria Haro
- Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM, Madrid, Spain; Institut de Recerca Sant Joan de Déu, Sant Boi de llobregat, Universitat de Barcelona, Barcelona, Spain
| | - Marion Leboyer
- Fondation FondaMental, French Scientific Foundation, Créteil, France; AP-HP, Department of Psychiatry of Mondor Hospital, DHU PePSY, Paris-Est-Créteil University (UPEC), Créteil, France; INSERM, U955, Translational Psychiatry, Créteil, France
| | - Karine Chevreul
- ECEVE, UMRS 1123, Université Paris Diderot, Sorbonne Paris Cité, INSERM, Paris, France; AP-HP, URC-Eco, DHU PePSY, F-75 004 Paris, France
| | | |
Collapse
|
2
|
Kamboj SK, Walldén YSE, Falconer CJ, Alotaibi MR, Blagbrough IS, Husbands SM, Freeman TP. Additive Effects of 3,4-Methylenedioxymethamphetamine (MDMA) and Compassionate Imagery on Self-Compassion in Recreational Users of Ecstasy. Mindfulness (N Y) 2018; 9:1134-1145. [PMID: 30100932 PMCID: PMC6061231 DOI: 10.1007/s12671-017-0849-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
3,4-Methylenedioxymethylamphetamine (MDMA;‘ecstasy’) produces prosocial subjective effects that may extend to affiliative feelings towards the self. Behavioural techniques can produce similar self-directed affiliation. For example, compassionate imagery (CI) and ecstasy reduce self-criticism and increase self-compassion to a similar extent, with the effects of CI enhanced in the presence of ecstasy. Here, we examine self-compassion and self-criticism in recreational users who consumed chemically verified MDMA in a within-subjects crossover study. In a naturalistic setting, polydrug-using participants performed a self-focused CI exercise on two occasions separated by ≥6 days: once having consumed self-sourced MDMA and once not. Effects on state self-criticism, self-compassion and emotional empathy were assessed before and after MDMA use (or over an extended baseline period on the occasion that MDMA was not consumed) and reassessed after CI. In participants (n = 20; 8 women) whose ecstasy contained MDMA and no other drug, CI and MDMA appeared to separately increase emotional empathy (to critical facial expressions) and self-compassion. The effects of CI and MDMA on self-compassion also appeared to be additive. Establishing the observed effects in controlled studies will be critical for determining the combined utility of these approaches in fostering adaptive self-attitudes in a therapeutic context.
Collapse
Affiliation(s)
- Sunjeev K Kamboj
- 1Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, Gower St., London, WC1E 6BT UK
| | - Ylva S E Walldén
- 1Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, Gower St., London, WC1E 6BT UK
| | - Caroline J Falconer
- 1Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, Gower St., London, WC1E 6BT UK
| | - Majdah Raji Alotaibi
- 2Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY UK
| | - Ian S Blagbrough
- 2Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY UK
| | - Stephen M Husbands
- 2Medicinal Chemistry, Department of Pharmacy and Pharmacology, University of Bath, Bath, BA2 7AY UK
| | - Tom P Freeman
- 1Clinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, Gower St., London, WC1E 6BT UK.,3Present Address: National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, 4 Windsor Walk, London, SE5 8BB UK
| |
Collapse
|
3
|
Woud ML, Blackwell SE, Steudte-Schmiedgen S, Browning M, Holmes EA, Harmer CJ, Margraf J, Reinecke A. Investigating d-cycloserine as a potential pharmacological enhancer of an emotional bias learning procedure. J Psychopharmacol 2018; 32:569-577. [PMID: 29446699 DOI: 10.1177/0269881118754679] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The partial N-methyl-D-aspartate receptor agonist d-cycloserine may enhance psychological therapies. However, its exact mechanism of action is still being investigated. Cognitive bias modification techniques allow isolation of cognitive processes and thus investigation of how they may be affected by d-cycloserine. We used a cognitive bias modification paradigm targeting appraisals of a stressful event, Cognitive Bias Modification-Appraisal, to investigate whether d-cycloserine enhanced the modification of appraisal, and whether it caused greater reduction in indices of psychopathology. Participants received either 250 mg of d-cycloserine ( n=19) or placebo ( n=19). As a stressor task, participants recalled a negative life event, followed by positive Cognitive Bias Modification-Appraisal training. Before and after Cognitive Bias Modification-Appraisal, appraisals and indices of psychopathology related to the stressor were assessed. Cognitive Bias Modification-Appraisal successfully modified appraisals, but d-cycloserine did not affect appraisals post-training. There were no post-training group differences in frequency of intrusions. Interestingly, d-cycloserine led to a greater reduction in distress and impact on state mood from recalling the event, and lower distress post-training was associated with fewer intrusions. Therefore, d-cycloserine may affect emotional reactivity to recalling a negative event when combined with induction of a positive appraisal style, but via a mechanism other than enhanced learning of the appraisal style.
Collapse
Affiliation(s)
- Marcella L Woud
- 1 Department of Psychology, Ruhr-Universität Bochum, Germany
| | | | | | | | - Emily A Holmes
- 4 Division of Psychology, Department for Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| | | | - Jürgen Margraf
- 1 Department of Psychology, Ruhr-Universität Bochum, Germany
| | | |
Collapse
|
4
|
Ye M, Du K, Zhou J, Zhou Q, Shou M, Hu B, Jiang P, Dong N, He L, Liang S, Yu C, Zhang J, Ding Z, Liu Z. A meta-analysis of the efficacy of cognitive behavior therapy on quality of life and psychological health of breast cancer survivors and patients. Psychooncology 2018; 27:1695-1703. [PMID: 29500842 DOI: 10.1002/pon.4687] [Citation(s) in RCA: 50] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2017] [Revised: 02/15/2018] [Accepted: 02/16/2018] [Indexed: 12/13/2022]
Abstract
OBJECTIVE The aim of this study was to examine the effect of cognitive behavior therapy (CBT) on quality of life (QOL) and psychological health of breast cancer survivors and patients. METHODS A total of 1289 references were examined from an overall literature search in PubMed, Embase, CINAHL, and the Cochrane Database of Systematic Reviews. Randomized controlled trials assessing the efficacy of CBT compared with a range of comparators in cancer survivors. We assessed the effect of CBT by using the standardized mean difference as effect size. RESULTS Among 1289 abstracts and 292 full-text articles reviewed, 10 studies were included. At the posttreatment period, the pooled effect size for CBT on QOL was 0.57 (95% CI, 0.44 to 0.69; P < .001), on depression was -1.11 (95% CI, -1.28 to -0.94; P < .001), on stress was -0.40 (95% CI, -0.53 to -0.26; P < .001), on anxiety was -1.10 (95% CI, -1.27 to -0.93; P < .001), and on hyperarousal cluster of symptoms was -0.18 (95% CI, -0.30 to -0.05; P < .001). The QOL was considered statistically medium effect sizes. The depression and anxiety were considered statistically large effect sizes. CONCLUSIONS Cognitive behavior therapy is an effective therapy for psychological symptoms of cancer survivors and patients, with meaningfully clinical effect sizes. These findings suggested that CBT should be used as the intervention for breast cancer survivors and patients when possible.
Collapse
Affiliation(s)
- Mengfei Ye
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China.,Department of Psychiatry, Shaoxing Seventh People's Hospital, Shaoxing, Zhejiang, China
| | - Kanghui Du
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China
| | - Jingying Zhou
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China
| | - Quanqian Zhou
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China
| | - Mengna Shou
- Department of Gynecology and Obstetrics, Shaoxing Women and Children's Hospital, Shaoxing, Zhejiang, China
| | - Baiqi Hu
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China
| | - Panruo Jiang
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China
| | - Nan Dong
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China
| | - Luying He
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China
| | - Shenglin Liang
- Department of Psychiatry, Shaoxing Seventh People's Hospital, Shaoxing, Zhejiang, China
| | - Chaoyang Yu
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China
| | - Jian Zhang
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China
| | - Zhinan Ding
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China.,Laboratory of Forensic Toxicology, Judicial Identification Center of Shaoxing University, Shaoxing, Zhejiang, China
| | - Zheng Liu
- Department of Clinical Medicine, Medical College of Shaoxing University, Shaoxing, Zhejiang, China.,Laboratory of Forensic Toxicology, Judicial Identification Center of Shaoxing University, Shaoxing, Zhejiang, China
| |
Collapse
|
5
|
Stroud JB, Freeman TP, Leech R, Hindocha C, Lawn W, Nutt DJ, Curran HV, Carhart-Harris RL. Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. Psychopharmacology (Berl) 2018; 235:459-466. [PMID: 29085980 PMCID: PMC5813058 DOI: 10.1007/s00213-017-4754-y] [Citation(s) in RCA: 58] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Accepted: 09/26/2017] [Indexed: 11/21/2022]
Abstract
RATIONALE Depressed patients robustly exhibit affective biases in emotional processing which are altered by SSRIs and predict clinical outcome. OBJECTIVES The objective of this study is to investigate whether psilocybin, recently shown to rapidly improve mood in treatment-resistant depression (TRD), alters patients' emotional processing biases. METHODS Seventeen patients with treatment-resistant depression completed a dynamic emotional face recognition task at baseline and 1 month later after two doses of psilocybin with psychological support. Sixteen controls completed the emotional recognition task over the same time frame but did not receive psilocybin. RESULTS We found evidence for a group × time interaction on speed of emotion recognition (p = .035). At baseline, patients were slower at recognising facial emotions compared with controls (p < .001). After psilocybin, this difference was remediated (p = .208). Emotion recognition was faster at follow-up compared with baseline in patients (p = .004, d = .876) but not controls (p = .263, d = .302). In patients, this change was significantly correlated with a reduction in anhedonia over the same time period (r = .640, p = .010). CONCLUSIONS Psilocybin with psychological support appears to improve processing of emotional faces in treatment-resistant depression, and this correlates with reduced anhedonia. Placebo-controlled studies are warranted to follow up these preliminary findings.
Collapse
Affiliation(s)
- J B Stroud
- Psychedelic Research Group, Neuropsychopharmacology Unit, Centre for Academic Psychiatry, Department of Medicine, Imperial College London, London, UK.
- Clinical Psychopharmacology Unit, University College London, London, UK.
| | - T P Freeman
- Clinical Psychopharmacology Unit, University College London, London, UK
- National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - R Leech
- Computational, Cognitive and Clinical Neuroscience Laboratory, Department of Medicine, Imperial College London, London, UK
| | - C Hindocha
- Clinical Psychopharmacology Unit, University College London, London, UK
| | - W Lawn
- Clinical Psychopharmacology Unit, University College London, London, UK
| | - D J Nutt
- Psychedelic Research Group, Neuropsychopharmacology Unit, Centre for Academic Psychiatry, Department of Medicine, Imperial College London, London, UK
| | - H V Curran
- Clinical Psychopharmacology Unit, University College London, London, UK
| | - R L Carhart-Harris
- Psychedelic Research Group, Neuropsychopharmacology Unit, Centre for Academic Psychiatry, Department of Medicine, Imperial College London, London, UK
| |
Collapse
|